IRP Research Leads to First FDA-Approved Therapy for Merkel Cell Carcinoma
Tuesday, May 4, 2021
May is Skin Cancer Awareness Month. Skin cancers are the most common cancer in the U.S., affecting as many as five million people every year. Yet the rarest of these cancers is also one of the deadliest. Merkel cell carcinoma affects about 3,000 Americans each year, and until recently a lack of effective treatments meant only half of patients survived five years or longer after diagnosis. The median survival was nine months.
This bleak outlook changed radically in 2017 with the US Food and Drug Administration (FDA) approval of a new immunotherapy drug called avelumab. Developed through a collaboration between IRP researchers and the pharmaceutical company EMD Serono, Inc., and marketed as Bavencio, avelumab was the first treatment approved specifically for Merkel cell carcinoma.
Future Physician-Scientists Spent a Year in IRP Labs
Monday, September 21, 2020
Many doctors not only treat patients directly, but also make valuable contributions to research that will improve medical care in the future. Each one of these talented ‘physician-scientists’ began his or her research career under the guidance of a more senior scientist. At the NIH, the Medical Research Scholars Program (MRSP) provides just such an experience to promising young medical students from all across the United States.
Study Also Reveals Immunotherapy’s Target on Cancer Cells
Tuesday, August 25, 2020
In the 1995 film The Usual Suspects, Kevin Spacey’s con man character famously remarks, “The greatest trick the Devil ever pulled was convincing the world he didn't exist.” The same could be said of cancer, which somehow persuades the body it is not a threat. Cutting-edge treatments called immunotherapies remove this façade and encourage the immune system to attack cancer cells. New IRP research in mice has demonstrated the promise of a new immunotherapy for treating ovarian cancer and identified a marker on cancer cells that could help clinicians identify patients who are most likely to benefit from the therapy.
Event Spotlights Students Completing Their Ph.D. Research in IRP Labs
Tuesday, February 25, 2020
The NIH provides an extraordinarily rich environment for learning and honing the skills needed to pursue a scientific career. It’s no wonder, then, that Ph.D. students from institutions all across the United States and the rest of the world come here to conduct their dissertation research under the mentorship of the IRP’s many renowned investigators.
Nearly 150 of those students presented the fruits of their scientific work at the NIH’s 16th annual Graduate Student Research Symposium on Thursday, February 20. The insights they have produced on topics from cancer to autoimmune disease to environmental contaminants were supremely impressive and will likely contribute to important improvements in medical care in the future. For anyone who missed this exciting event, read on to learn about a few of the many research projects that were on display.
Exceptional Early-Stage Investigators Push the Boundaries of Translational Research
Thursday, December 5, 2019
Online and print publications are constantly touting momentous discoveries by superstar scientists like CRISPR-Cas9 co-discover Jennifer Doudna or the IRP’s own Kevin Hall, who changed the way we think about weight loss. It can be easy to forget that today’s biomedical pioneers were once young researchers toiling to establish themselves in the competitive environment of modern science.
Each year, a small, exceptionally promising group of scientific up-and-comers become Lasker Clinical Research Scholars through a highly competitive program jointly funded by the NIH and the Albert and Mary Lasker Foundation. The program presents early-stage physician-scientists with the opportunity to carry out independent clinical research at the NIH for five to ten years. The 2019 class of Lasker Scholars consists of five extremely talented researchers who are now beginning a critical new phase in their careers. Let’s meet them.
Annual Event Shares Research by IRP’s Summer Interns
Tuesday, August 13, 2019
NIH’s Natcher Conference Center was packed once again last Thursday for the annual Summer Poster Day. This year, more than 1,200 college and high school students spent their summer performing research in an IRP lab through the NIH’s Summer Internship Program.
I navigated through the more than 900 posters presented this year to get a taste of the impressive work done by these young men and women in less than three months. If they can make these kinds of discoveries in just one summer, imagine what they might one day accomplish as full-time scientists and clinicians!
Tuesday, July 17, 2018
The constant combat between cancer and the body’s defenses can wear a tumor out. Unfortunately, cancer cells can pause their life cycle to repair themselves before re-entering the fray with renewed vigor. According to new IRP research, preventing cancer from taking a time-out can make it more susceptible to attack by the immune system.
Tuesday, April 4, 2017
Last month I moderated our annual retreat with the NIH Scientific Directors, those individuals tasked with leading their Institute or Center (IC)-based intramural research program. We were joined by many of the IC Clinical Directors. And this year we decided to do something a little different: listen to a series of talks about exciting, new IRP research.
Tuesday, January 26, 2016
In his recent State of the Union address, President Barack Obama called America to action and asserted that our researchers can find the cure for cancer, a sentiment that received a standing ovation. We believe that Obama is right.
Wednesday, October 7, 2015
The Partnership for Public Service has awarded Steven A. Rosenberg, M.D., chief of the Surgery Branch in NCI's Center for Cancer Research, with its highest 2015 Samuel J. Heyman Service to America Medal, or Sammie, for his research to develop life-saving immune-based therapies for patients with advanced cancers.